The RPS6KA2 antibody targets the ribosomal protein S6 kinase A2 (RPS6KA2), also known as mitogen- and stress-activated protein kinase 1 (MSK1) or MAPKAP-K1. This serine/threonine kinase is activated by the MAPK signaling pathways, including ERK and p38. in response to growth factors, stress, or cytokines. RPS6KA2 phosphorylates substrates like CREB and NF-κB, regulating gene transcription linked to cell proliferation, survival, differentiation, and inflammatory responses. Structurally, it contains two kinase domains and a C-terminal regulatory region, enabling interactions with signaling complexes.
RPS6KA2 is implicated in neurological development and disorders, with studies associating its dysfunction with autism spectrum disorders, schizophrenia, and intellectual disability. It also plays roles in cancer, where its dual pro- or anti-tumor effects depend on cellular context. The RPS6KA2 antibody is widely used in research to detect protein expression, localization, and activation in tissues or cultured cells via techniques like Western blot, immunohistochemistry, and immunofluorescence. Its application aids in elucidating RPS6KA2's involvement in disease mechanisms and potential therapeutic targeting. This antibody serves as a critical tool for exploring kinase-driven signaling networks and their pathological implications.